Valproic Acid Serum Concentration and Incidence of Toxicity in Pediatric Patients

Area of Science:

• Pediatric Neurology
• Pharmacology
• Clinical Therapeutics

Background:

• Valproic acid is a key antiepileptic drug for pediatric patients.
• Higher serum concentrations are sometimes used to optimize seizure control.
• Potential adverse effects necessitate careful monitoring of valproic acid levels.

Purpose of the Study:

• To evaluate the incidence of common adverse effects of valproic acid (thrombocytopenia, hepatotoxicity, hyperammonemia).
• To compare these adverse effects across different maintenance serum valproic acid concentration ranges (50-120 μg/mL).
• To assess the influence of age group (prepubescent, pubescent, postpubescent) on these adverse effects.

Main Methods:

• Retrospective chart review of 124 pediatric patients on maintenance valproic acid therapy.
• Patients categorized into three serum concentration groups: 50-80, 80-100, and 100-120 μg/mL.
• Patients also categorized into three age groups: prepubescent, pubescent, and postpubescent.

Main Results:

• No statistically significant differences in thrombocytopenia incidence were found across serum concentration groups (P=.093) or age groups (P=.628).
• Hepatic dysfunction and hyperammonemia showed no significant differences across serum concentration groups (P=.099 and P=.548, respectively).
• Age group analysis also revealed no significant differences in hepatic dysfunction (P=.615) or hyperammonemia (P=.369).

Conclusions:

• Serum valproic acid levels exceeding 100 μg/mL can be considered in select pediatric patients for enhanced seizure control.
• This approach may be safe, as common adverse effects were not significantly increased at higher concentrations or across different age groups.
• Individualized therapeutic drug monitoring is crucial for optimizing valproic acid treatment in children.